問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberSGNDV-001
Active

2023-12-01 - 2029-04-30

Phase III

Recruiting9

ICD-10C79.10

Secondary malignant neoplasm of unspecified urinary organs

ICD-10C79.11

Secondary malignant neoplasm of bladder

ICD-10C79.19

Secondary malignant neoplasm of other urinary organs

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9198.1

Secondary malignant neoplasm of other urinary organs

  • Trial Applicant

    Pharmaceutical Research Associates Taiwan Inc.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator Wen-Pin Su Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Jian-Ri Li Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 呂長賢 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 曹朝榮 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yu-Chieh Tsai Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 康智雄 Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 黃文冠 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chao-Hsiang Chang Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wen-Jeng Wu Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    22 participants

  • Global

    700 participants